Roche Weight-Loss Injection Mid-Stage Trial: 15.5% Weight Reduction Over 48 Weeks With No Plateau
nashnova research
Roche released mid-stage data for its obesity injection enicepatide — the highest-dose group lost 15.5% of body weight over 48 weeks with no plateau in sight, marking the company's formal entry into the $150 billion weight-loss drug race against Eli Lilly and Novo Nordisk.
How strong is this data?
Patients with type 2 diabetes and obesity on the highest 24 mg dose lost an average of 15.5% of body weight over 48 weeks; HbA1c — a blood-sugar control marker — dropped 2.65%.
The standout detail: the weight-loss curve showed no plateau at week 48. This means → if treatment continues, the final reduction could go higher still.
In plain terms = many weight-loss drugs hit a ceiling around six months where the scale stops moving; enicepatide hasn't hit that wall yet.
How does it compare to Lilly and Novo?
Enicepatide works like Eli Lilly's Zepbound: both activate GLP-1 and GIP receptor pathways simultaneously — a "two-lever" approach that regulates appetite and metabolism at the same time.
Novo Nordisk's semaglutide targets only GLP-1. Both Lilly and Roche bet on dual-pathway activation. This reflects an industry consensus shifting toward "two targets beat one."
The global weight-loss drug market could reach $150 billion. Roche's data release signals a third heavyweight has officially entered the ring.
What about safety?
The most common side effects were mild-to-moderate gastrointestinal reactions — nausea, diarrhea — and were broadly manageable.
Only 2.0% of patients in the treatment group dropped out due to side effects, versus 0% in the placebo group.
In plain terms = the main downside is stomach discomfort; the number of people who found it bad enough to quit was very low — roughly in line with rival drugs.
Where did this drug come from, and what did Roche pay?
Enicepatide was originally CT-388, developed by Carmot Therapeutics. Roche acquired the company in 2023 for $3.1 billion.
Bloomberg Intelligence analysts project the drug could win approval as early as 2030, with peak annual sales of about $4 billion.
This means → Roche paid $3.1 billion to bet on a product with a $4 billion peak — the return multiple hinges on clearing the remaining clinical hurdles.
What comes next?
Roche plans to launch Phase III trials and a cardiovascular-outcomes study in the first half of 2027.
Whether Phase III data can demonstrate cardiovascular benefits beyond weight loss will be the make-or-break milestone. This means → shedding pounds alone isn't enough; proving the drug also cuts heart-disease risk would unlock a much larger market value.
Roche Chief Medical Officer Levi Garraway said enicepatide "has the potential to be a best-in-disease treatment that can reduce and prevent complications."
Combined with sustained weight loss, enicepatide has the potential to be a best-in-disease treatment that can reduce and prevent complications and improve metabolic health for people living with type 2 diabetes.
Levi Garraway
Chief Medical Officer & Head of Global Product Development, Roche
(Roche mid-stage clinical data release)
市场有风险，内容仅供研究参考，不构成投资建议。